Quarterly ResultMay 15, 2026, 05:16 PM
TuHURA Secures $50M Credit Facility; Reports Q1 Results
AI Summary
TuHURA Biosciences reported its first quarter 2026 financial results and provided a corporate update, highlighted by securing a $50 million non-equity-based credit facility and royalty transaction. This financing extends the company's anticipated cash runway into 2028, allowing it to fund operations beyond anticipated top-line data in its lead IFx-2.0 program. The company also announced key management appointments and received FDA Orphan Drug Designation for IFx-2.0 for the treatment of stage IIB to stage IV cutaneous melanoma, alongside outlining several upcoming pipeline milestones.
Key Highlights
- Secured a $50 million non-equity-based credit facility and royalty transaction, extending cash runway into 2028.
- Credit facility bears a 12% annual interest rate on outstanding funds, with principal due April 21, 2031.
- Cash and cash equivalents were $6.3 million at March 31, 2026.
- Research and development expenses increased to $5.2 million in Q1 2026 from $4.6 million in Q1 2025.
- General and administrative expenses rose to $2.3 million in Q1 2026 from $2.0 million in Q1 2025.
- Net cash outflows from operating activities were ($4.4) million in Q1 2026.
- Net cash flows from financing activities were $7.2 million in Q1 2026.
- Received FDA Orphan Drug Designation for IFx-2.0 for stage IIB to stage IV cutaneous melanoma.
- Appointed Craig Tendler, M.D., as Chief Medical Officer and Amanda Garofalo as Senior Vice President of Clinical Operations.
Price Impact
More from HURA